Biopharma IPO Numbers Kept Rising In Q3 As Deal Sizes, Valuations Shrank
Third quarter data from Evaluate show nine biopharma initial public offerings on Western exchanges totaling $2.39bn. Average US deal sizes were down from prior quarters as falling valuations likely impacted investors’ IPO appetites.
Scrip - October 14, 2026

Arrowhead To Move Onto Alzheimer’s After ARO-MAPT Success In Healthy Volunteers
Phase I/IIa data for the siRNA drug showed it can cross the blood-brain barrier when administered via subcutaneous injection, with better delivery than with intrathecal administration.
Scrip - October 14, 2026

Gilead Widens Cancer Bets With Vir Deal On Masked T-Cell Engagers
Deal Snapshot: Vir will apply its PRO-XTEN masking technology to build T-cell engagers against three solid-tumor targets selected by Gilead, in a deal worth up to nearly $1.9bn.
Scrip - October 14, 2026

Beyond Harvesting: How Pfizer Is Using Mature Brands As A Test Bed For Innovation
Senior Pfizer executive outlines how the company is using its mature and established brands as a beachhead to test new business and technology models, unlocking value for that portfolio while generating lessons for the broader firm.
Scrip - October 14, 2026

BioJapan: Japanese Ventures Expand Horizons In Radiopharma, Neuron-Targeted Delivery
BioJapan shines spotlight on domestic ventures including LinqMed and its pre-NDA radioisotope for malignant glioma and Jiksak's novel neuron-targeting drug delivery technology.
Scrip - October 14, 2026

Finance Watch: 2026 Biopharma IPO Total Doubles Last Year’s Number
Public Company Edition: TRexBio and Retension grossed $116.7m and $45m, respectively, in the third quarter’s first two initial public offerings, bringing the US IPO total to 24 so far in 2026 versus 12 for all of 2025. In other financings, Vaxcyte closed a $1.15bn follow-on offering.
Scrip - October 14, 2026

Chiropractor Sentenced To 14 Years For Role In $30M DME Billing Fraud
An Oklahoma chiropractor is set to serve 14 years in prison for his role at the center of a durable medical equipment fraud scheme that billed federal healthcare programs for $30m in unnecessary equipment, collecting $8m.
Medtech Insight - October 14, 2026

Consumer Health Firms Should Shape AI Standards For Self-Care Products, Expert Says
Barry Chaiken says AI chatbots are eroding guided self-care and that the industry, rather than tech companies, should set standards for how products are used.
Medtech Insight - October 14, 2026

Early QMSR Lessons, AI Oversight And RWE On Regulatory Agenda At AdvaMed’s MedTech Conference
The MedTech Conference, hosted by AdvaMed, will bring more than 4,000 industry leaders to Boston Oct. 18–21 to discuss major medtech trends including AI, real-world evidence, regulatory policy, quality systems and global market access.
Medtech Insight - October 14, 2026

‘AI-Native’ Notified Body Scarlet Bucks Sector Woes With $50m Funding
Scarlet specializes in certifying AI-enabled medical devices as well as paring assessors with AI agents for greater speed.
Medtech Insight - October 14, 2026

Bausch + Lomb’s Few Words On CEO Change Leave Questions About FDA Warning Unanswered
Brent Saunders apparently wasn’t a cog in B+L’s confidence in expecting to increase its full-year guidance. Canadian firm marketing OTC eye drops Biotrue, Blink, Lumify and Soothe in US also didn’t note it was working on an acquisition.
HBW Insight - October 15, 2026

BEMT Could Move SPF In US From Beach Bag To Daily Routine – DSM-Firmenich
Dsm-firmenich’s Carl D’Ruiz explains during an Oct. 14 webinar how BEMT is enabling US formulators to make more creative and lighter sunscreens, as the Swiss-Dutch ingredients and innovation company launches its RADIANCE & GLOW face and lip collection with the active.
HBW Insight - October 15, 2026

UK Amoxicillin Prices Spike As Rivastigmine Continues To Climb
As steep price rises continue to be a fixture of the UK generics market – with multiple molecules in different presentations seeing their average prices doubling, trebling or even more than quadrupling in September – Generics Bulletin and WaveData look at the latest trends.
Generics Bulletin - October 14, 2026

Biocon Claims Earliest Pertuzumab Launch Dates With Perjeta Settlement
Following a recent endorsement from the EMA, Biocon has moved to secure launch dates for its Pebrilzo biosimilar to Perjeta across the world, including a Q1 2027 launch in Europe. But with Organon already holding EU and US approvals for its own Henlius-partnered pertuzumab Poherdy, a showdown looms.
Generics Bulletin - October 14, 2026

Xbrane Edges Closer To Opdivo Biosimilar Finish Line With Completed Trial Recruitment
Xdivane, a nivolumab biosimilar co-developed by Xbrane and Intas, has reached a trial recruitment milestone, as approvals in the US and Europe are anticipated as soon as Opdivo exclusivity ends.
Generics Bulletin - October 14, 2026

Taming AAV Immunogenicity Is Gene Therapy’s Defining Challenge
AAV gene therapy has transformed outcomes for patients with rare diseases, but immune responses to the vector are limiting who can be treated, how safely, and for how long. Genethon’s Klaudia Kuranda explains how her organization is attacking the problem from several angles at once.
In Vivo - October 14, 2026